Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus

Clinical Rheumatology

Volumn 25, Issue 3, 2006, Pages 347-352

  van den Berg, Loes ^a   Nossent, Hans ^a   Rekvig, Ole ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anti dsDNA antibodies; Disease flares; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE;

ADULT; ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; KIDNEY DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEALTH STATUS; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 33645762024     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-005-0047-7     Document Type: Article

References (36)

1. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271-1277
2. Hahn BH (1998) Antibodies to DNA. N Engl J Med 338(19):1359-1368
3. Pisetsky DS (1998) Anti-DNA antibodies in systemic lupus erythematosus: a case of mistaken identity? J Rheumatol 25(2):195-197
4. Rekvig OP, Andreassen K, Moens U (1998) Antibodies to DNA - towards an understanding of their origin and pathophysiological impact in systemic lupus erythematosus. Scand J Rheumatol 27(1):1-6
5. Isenberg DA, Ravirajan CT, Rahman A, Kalsi J (1997) The role of antibodies to DNA in systemic lupus erythematosus - a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Lupus 6(3):290-304
6. Rekvig OP, Nossent JC (2003) Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: A time for new paradigms? Arthritis Rheum 48(2):300-312
7. Ho A, Magder LS, Barr SG, Petri M (2001) Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 44(10):2342-2349
8. Ho A, Barr SG, Magder LS, Petri M (2001) A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 44(10):2350-2357
9. Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TE (1979) Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 22(3):226-235
10. Swaak AJ, Groenwold J, Bronsveld W (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45(5):359-366
11. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33(5):634-643
12. Bootsma H, Spronk PE, ter Borg EJ, Hummel EJ, de Boer G, Limburg PC et al (1997) The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis 56(11):661-666
13. Williams RC Jr, Malone C, Blood B, Silvestris F (1999) Anti-DNA and anti-nucleosome antibody affinity - a mirror image of lupus nephritis? J Rheumatol 26(2):331-346
14. Zonana-Nacach A, Roseman JM, McGwin G Jr, Friedman AW, Baethge BA, Reveille JD et al (2000) Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. LUpus in MInority populations: NAture vs nurture. Lupus 9(2):101-109
15. Kavanaugh A (2001) The utility of immunologic laboratory tests in patients with rheumatic diseases. Arthritis Rheum 44(10):2221-2223
16. Kavanaugh AF, Solomon DH (2002) Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-DNA antibody tests. Arthritis Rheum 47(5):546-555
17. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE (1996) Routine immunologic tests in systemic lupus erythematosus: Is there a need for more studies? J Rheumatol 23(11):1891-1896
18. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D (1996) Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 39(3):370-378
19. Rauch J, Hazeltine M, Tannenbaum H, Danoff D, Isenberg DA, Wild J et al (1990) Association of anti-DNA idiotype markers with clinical and serological manifestations in patients with systemic lupus erythematosus. J Rheumatol 17(2):178-185
20. Nossent HC (2001) Systemic lupus erythematosus in the Arctic region of Norway. J Rheumatol 28(3):539-546
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630-640
22. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1994) Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: International validation. J Rheumatol 21(8):1468-1471
23. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1992) Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 19(4):608-611
24. Haugbro K, Nossent JC, Winkler T, Figenschau Y, Rekvig OP (2004) Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: The role of analytical diversity. Ann Rheum Dis 63(4):386-394
25. Olaussen E, Rekvig OP (1999) Screening tests for antinuclear antibodies (ANA): Selective use of central nuclear antigens as a rational basis for screening by ELISA. J Autoimmun 13(1):95-102
26. Aarden LA, de Groot ER, Feltkamp TE (1975) Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 254:505-515
27. Spronk PE, Bootsma H, Kallenberg CG (1998) Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment? Clin Rev Allergy Immunol 16(3):211-218
28. Swaak AJ, Nossent JC, Smeenk RJ (1991) Prognostic factors in systemic lupus erythematosus. Rheumatol Int 11(3):127-132
29. Petri M (1995) Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 7(5):395-401
30. Petri M, Barr SG, Zonana-Nach A, Magder L (1999) Measures of disease activity, damage, and health status: The Hopkins Lupus Cohort experience. J Rheumatol 26(2):502-503
31. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J et al (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345(8965):1595-1599
32. Arce-Salinas A, Cardiel MH, Guzman J, Alcocer-Varela J (1996) Validity of retrospective disease activity assessment in systemic lupus erythematosus. J Rheumatol 23(5):846-849
33. FitzGerald JD, Grossman JM (1999) Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 8(8):638-644
34. Barr SG, Zonana-Nacach A, Magder LS, Petri M (1999) Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 42(12):2682-2688
35. Wluka AE, Liang MH, Partridge AJ, Fossel AH, Wright EA, Lew RA et al (1997) Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation. Arthritis Rheum 40(1):57-61
36. Haga HJ, Brun JG, Rekvig OP, Wetterberg L (1999) Seasonal variations in activity of systemic lupus erythematosus in a subarctic region. Lupus 8(4):269-273